newsfilter
← Earnings
Earnings Releases·

Aptevo Therapeutics — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Cash and cash equivalents totaled $8.3 million as of September 30, 2026, a decrease from $9.8 million as of June 30, 2026.
    • Net loss for the third quarter of 2026 was $6.5 million, compared to a net loss of $7.5 million in the third quarter of 2025.
    • Financing activity in August 2026 generated gross proceeds of approximately $4.5 million, or approximately $4.1 million net of $0.4 million in issuance costs.
  • Guidance and Future Outlook:

    • The RAINIER Phase 1b dose optimization study completion is targeted by year-end 2026.
    • Regulatory interaction is planned for the first half of 2027.
    • Preclinical molecules (APVO451 and radiopharmaceutical programs) are expected to advance into investigational new drug (IND)-enabling studies in 2027.
    • The company aims to translate clinical strength into long-term value for shareholders as it approaches important development milestones.
  • Business Segments and Product Lines:

    • Mipletamig achieved a 79% remission rate (CR or CRi) in 14 evaluable patients with TP53-mutated AML treated in combination with venetoclax and azacitidine.
    • Ten of 47 patients receiving mipletamig combination therapy advanced to potentially curative stem cell transplantation.
    • A refined priming-dose regimen significantly reduced infusion-related reactions, improving tolerability for the mipletamig triplet.
    • Next-generation trispecifics are advancing toward human testing, with manufacturing optimization supporting scale-up for solid tumor candidates.
    • A new patent application covering Nectin-4 × PD-L1 dual-targeting technology was filed to support immune-based therapies and radiopharmaceuticals.
    • A strategic collaboration with Niowave is underway to develop up to three radiopharmaceutical oncology programs targeting nectin-4.
  • Market and Competitive Landscape:

    • The observed 79% CR/CRi rate for mipletamig compares favorably with a published 41% composite remission rate for treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML treated with venetoclax plus azacitidine.
    • Mipletamig has received orphan drug designation for AML under the Orphan Drug Act.
    • The company is expanding opportunities beyond AML to treat solid tumors using its multispecific technology platform.
  • Risks and Challenges:

    • Forward-looking statements note that actual results may differ due to factors including deterioration in business or prospects, adverse events, unexpected safety issues in clinical trials, and changes in regulatory, social, macroeconomic, and political conditions.
    • Preliminary or interim data may be reassessed, or later clinical trials may yield different results.
    • The success of the strategy in translating to improved overall survival rates, particularly in patient subgroups with poor prognosis, remains subject to future study.
  • Management Commentary and Tone:

    • CEO Jeff Lamothe stated the company is entering an "exciting period" with growing clinical evidence reinforcing confidence in mipletamig.
    • Management highlighted strong clinical activity in difficult-to-treat AML forms, patients advancing to curative transplants, and improved tolerability.
    • Management expressed conviction that mipletamig has the potential to become an important addition to frontline AML treatment.
    • The tone emphasized the company's position to translate the strength of its science into meaningful opportunities for patients and shareholders.
  • Other Key Points:

    • In August 2026, existing warrant holders exercised warrants for 254,922 shares at $4.03 per share and purchased 861,708 additional shares (or pre-funded warrants) at the same price in a private placement.
    • Investors received new warrants covering up to 5,583,150 shares at $4.03 per share, which could provide up to $22.5 million in additional proceeds if exercised.
    • The company's eight pipeline candidates are generated using proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms.
    • Mipletamig is currently being evaluated in the RAINIER trial, a two-part Phase 1b/2 trial for frontline AML.
Company
APTEVO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology